HIND Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: March 23, 2026
Report Source: 2025 Annual Report
Vyome Holdings Inc. Stock Analysis HIND
Vyome Holdings, Inc. engages in the development of immuno-inflammatory assets. The company is headquartered in San Clemente, California and currently employs 9 full-time employees. The company went IPO on 2016-10-06. The firm is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.
Read More Vyome Holdings Inc (HIND) Chart
Key Statistics of Vyome Holdings Inc (HIND)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$1.93Volume
21.92KP/E Ratio (TTM)
-52 Week Range
Market Cap
14.53MAvg. Volume
35.20KDividend Yield
-Financial Metrics & Statements of Vyome Holdings Inc (HIND)
FAQ's for Vyome Holdings Inc (HIND)
- According to Musaffa’s Shariah screening methodology, Vyome Holdings Inc (HIND) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.